Login

Financial Snapshot

Revenue
TTM
$629.2M
Gross Margin
TTM
48.46%
Net Income
TTM
$53.82M
Current Assets
2024 Q1
$1.303B
Current Liabilities
2024 Q1
$361.1M
Current Ratio
2024 Q1
360.95%
Total Assets
2024 Q1
$2.162B
Total Liabilities
2024 Q1
$369.1M
Book Value
2024 Q1
1.793B
Cash
2024 Q1
$362.9M
P/E
TTM
30.01
Free Cash Flow
TTM
$70.31M

Stock Price

Loading...
Market Cap: $1.615 Billion

About TARO PHARMACEUTICAL INDUSTRIES LTD

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. The firm operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The firm markets over 200 pharmaceutical products in over 25 countries. The firm's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The firm's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Industry: Pharmaceutical Preparations Peers: Mediwound Ltd Sol Gel Technologies Ltd

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support